Plasma Aβ but not tau is related to brain PiB retention in early Alzheimer's disease
Journal
ACS Chemical Neuroscience
Journal Volume
5
Journal Issue
9
Pages
830-836
Date Issued
2014
Author(s)
KAI-YUAN TZEN
Yang S.-Y.
Cheng T.-W.
Horng H.-E.
Wen H.-P.
Huang Y.-Y.
Shiue C.-Y.
Abstract
Recent advances in biomarkers provide the possibility of early or preclinical diagnosis of Alzheimer's pathology. Currently, decreased levels of Aβ-42 and increased levels of tau proteins in cerebral spinal fluid are considered reliable biomarkers of Alzheimer's disease (AD); however, little evidence exists for the use of amyloid and tau protein levels in the plasma as useful biomarkers. We investigated the potential use of plasma biomarkers to diagnose AD and explored their relationships with brain Aβ deposition in amyloid imaging. We used an immunomagnetic reduction assay to measure the plasma levels of Aβ40, Aβ42, and tau proteins in 20 older control participants and 25 participants who had either mild cognitive impairment due to AD or early AD dementia. All participants received 11C-labeled Pittsburgh compound B PET scans. The sensitivity of the plasma tau level at the cutoff value of 28.27 pg/mL was 92%, and the specificity was 100%; the sensitivity of the Aβ42/40 ratio at the cutoff value of 0.3693 was 84%, and the specificity was 100%. Regression analyses of the effects of plasma protein levels on brain amyloid retention, as determined by standard uptake value ratios in either side of the frontal, parietal, and temporal lobes and the precuneus, are predicted only by ratios of plasma Aβ42/40 (R2 0.326-0.449, all p < 0.001) but not by plasma tau levels. Plasma Aβ in terms of Aβ42/40 might provide an indirect estimation of Aβ deposition in the brain. ? 2014 American Chemical Society.
SDGs
Other Subjects
amyloid beta protein[1-40]; amyloid beta protein[1-42]; brain protein; Pittsburgh compound B; tau protein; amyloid beta protein; amyloid beta protein[1-40]; amyloid beta-protein (1-42); benzothiazole derivative; N-methyl-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole; peptide fragment; tau protein; adult; age; Alzheimer disease; amyloid beta deposition; Article; clinical article; Clinical Dementia Rating; controlled study; education; female; frontal lobe; gender; human; immunoassay; immunomagnetic reduction assay; male; mild cognitive impairment; Mini Mental State Examination; neuropathology; parietal lobe; positron emission tomography; precuneus; priority journal; protein blood level; protein localization; sensitivity and specificity; temporal lobe; aged; Alzheimer disease; blood; brain; chi square distribution; metabolism; middle aged; neuropsychological test; pathology; psychological rating scale; regression analysis; scintiscanning; Aged; Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Brain; Chi-Square Distribution; Female; Humans; Male; Middle Aged; Mild Cognitive Impairment; Neuropsychological Tests; Peptide Fragments; Psychiatric Status Rating Scales; Regression Analysis; tau Proteins
Publisher
American Chemical Society
Type
journal article